NUCLEOLIN and lung adenocarcinoma: Further analysis of the patient distribution within staging and TMN grading as a function of nucleolin expression (based on OS data from whole cohorts) demonstrated that nucleolinhigh lung adenocarcinoma cases are more prevalent (p < 0.01) at higher staging (50, 54, and 56% of the cases in Stage II, III, and IV, respectively), than in stage I (37% of cases) (Figure S2A).